• Email Us: [email protected]
  • Contact Us: +1 718 874 1545
  • Skip to main content
  • Skip to primary sidebar

Medical Market Report

  • Home
  • All Reports
  • About Us
  • Contact Us

IsoPlexis, a company uncovering a ‘new layer’ of cell data, aims for $125M in market debut

October 8, 2021 by David Barret Leave a Comment

Shares of IsoPlexis, a company creating tools to zoom in on the flurry of protein activity surrounding a single cell, began trading on Friday. The company aims to raise about $125 million with the IPO, which will be used to build the commercial team and advance the company’s plans to play a bigger part in the creation of precision medicine. 

IsoPlexis was founded in 2013 and fits into the category of companies you might find in a lab during the drug research process. The company is primarily focused on single-cell proteomics (basically the study of proteins and their interactions). The company has developed instruments and software to analyze the proteins secreted by cells, from immune cells to tumor cells.

In particular, the instruments can be used to identify cells that excrete many different types of proteins. These datasets could then be used to develop new treatments or understand how people may respond to existing ones. 

“Our instrument we invented is able to identity subsets of cells in the body we call superhero cells,” explains CEO and co-founder Sean MacKay. “And these superhero cells are defined by a lot of activity coming from small subsets of cells you would normally miss with existing technologies today.”

MacKay says there are about 150 IsoPlexis units on the market as of the first half of this year. Customers include 15 global pharmaceutical companies, and, per SEC filings, nearly half of the comprehensive cancer centers in the U.S. 

IsoPlexis has raised a considerable amount of funding in the past from some notable investors. 

Pre-IPO, the company had secured about $205.5 million in funding, per Crunchbase. The most recent Series D round totaled about $135 million in financing (about $85 million in equity securities and $50 million in debt financing), and included participation from Perceptive Advisors, Ally Bridge Group, and “funds and accounts” managed by BlackRock. 

Today, shares were initially priced around $15 each, but have slid to about $12 as of writing.

A major part of IsoPlexis thesis is they’re the first to use proteomics and single-cell biology to link the function of cells to patient outcomes. Or in other words, among the first to show that we might be able to tell how well someone like a cancer patient may fare, by examining how individual cells and proteins interact. 

There is published evidence that IsoPlexis’ instruments have been used to this effect, particularly when it comes to cancer treatments. 

For example, one 2021 Nature Medicine study used IsoPlexis instruments to examine immune cell activity in lymphoma patients. These patients had cancers resistant to treatment, or that had returned after remission. Specifically, they were receiving CAR-T cell therapy – a form of treatment where genetically engineered immune cells are injected into a patient, where they then help target cancerous cells. Ultimately, the study found that cytokine production (proteins involved in cell signaling), by those CAR-T cells was an important indicator of how potent those CAR-T cells actually were.

In essence, it showed that IsoPlexis’ device might help uncover the signals that tell scientists how well CAR-T cell therapy was working. 

“What we’ve seen is that the unique cells we identify are indicative of a long-term response in patients,” says MacKay. “We published studies in various cancers where, if patients have these types of unique immune cells, these superhero cells we detect, we know that those patients are going to have this long term outcome.” 

For people particularly interested in the minutia of cells, IsoPlexis technology might sound similar to flow cytometry – a well-established method of counting cells, identifying them, and measuring specific cell characteristics. There are some large established players in the flow cytometry world, like Thermo Fisher Scientific. 

IsoPlexis, though, argues it can offer a whole new layer of information, largely, protein-based information, that flow cytometry misses. The company has licensed an invention that allows the devices to barcode protein activity present in each individual cell (now called IsoCode). One Nature Reviews Chemistry paper suggests that barcoding is useful because it can analyze many different proteins at once, across thousands of cells, and cells can be recovered to be used in other experiments – but that this technology can still only capture a piece of the overall action of the proteome, so far. 

 “That new layer of data, for an individual cell is very different from the technology that is on the market today,” MacKay adds. 

Still, the company still has a long way to go before it can reach profitability. Per SEC documents, the company has been running a loss for the past several years. Though the company pulled in $7.5 million in revenue in 2019 and $10.4 in 2020, it lost about $13.6 million and $23.3 million in those years, respectively. 

Going forward, the path to growth largely means getting more instruments into more researchers’ hands. 

“Our goal is to continue to move forward at a fast clip, expanding the same type of customers we have currently, but with more depth, and that’s really by continuing to build a commercial team,” he says. 

Source Link IsoPlexis, a company uncovering a ‘new layer’ of cell data, aims for $125M in market debut

David Barret
David Barret

Related posts:

  1. End of the summer: Events that may shake markets in September
  2. Lukewarm: rich states set to fall short of $100 billion climate funding goal
  3. It’s time to end the war at home for troops with traumatic brain injuries
  4. U.S. says return to Vienna nuclear talks with Iran must happen soon

Filed Under: News

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Primary Sidebar

  • Bright Northern Lights Across America Expected This Week As 3 Coronal Mass Ejections Fly Towards Earth
  • Brain Implant Enables Paralyzed Man To Feel And Use Objects Using Someone Else’s Hands
  • “This Is A Really Big Deal”: Brain Training Significantly Improves Key Neurochemical Levels In World First
  • “Wholly Unexpected”: First-Ever Fossil Paranthropus Hand Raises Questions About Earliest Tool Makers’ Identity
  • For Centuries, Nobody Knew Why Swiss Cheese Has Holes. Then, The Mystery Was Solved.
  • Scientists Studied The Infamous “Chicago Rat Hole” And They Have Some Bad News
  • Massive 166-Million-Year-Old Sauropod Footprints Become The Longest Dinosaur Trackway In Europe
  • Do Spiders Dream? “After Watching Hundreds Of Spiders, There Is No Doubt In My Mind”
  • IFLScience Meets: ESA Astronaut Rosemary Coogan On Astronaut Training And The Future Of Space Exploration
  • What’s So Weird About The Methuselah Star, The Oldest We’ve Found In The Universe?
  • Why Does Red Wine Give Me A Headache? Many Scientists Blame It On The Grape Skins
  • Manta Rays Dive Way Deeper Than We Thought – Up To 1.2 Kilometers – To Explore The Seas
  • Prof Brian Cox Explains What He Finds “Remarkable” About Interstellar Object 3I/ATLAS Story
  • Pioneering “Pregnancy Test” Could Identify Hormones In Skeletons Over 1,000 Years Old
  • The First Neolithic Self-Portrait? Stony Human Face Emerges In 12,000-Year-Old Ruins At Karahan Tepe
  • Women Are Diagnosed With ADHD 5 Years Later Than Men, Even With Worse Symptoms
  • What Is Cryptozoology? We Explore The History And Mystery Of This Controversial Field
  • The Universe’s “Red Sky Paradox” Just Got Darker: Most Stars Might Never Host Observers
  • Uranus And Neptune May Not Be “Ice Giants” But The Solar System’s First “Rocky Giants”
  • COVID-19 Can Alter Sperm And Affect Brain Development In Offspring, Causing Anxious Behavior
  • Business
  • Health
  • News
  • Science
  • Technology
  • +1 718 874 1545
  • +91 78878 22626
  • [email protected]
Office Address
Prudour Pvt. Ltd. 420 Lexington Avenue Suite 300 New York City, NY 10170.

Powered by Prudour Network

Copyrights © 2025 · Medical Market Report. All Rights Reserved.

Go to mobile version